ARTELO BIOSCIENCES, INC. (ARTL): Nasdaq/NYSE listing notice — Artelo Biosciences receives Nasdaq delisting notice for missing annual meeting deadline

ARTELO BIOSCIENCES, INC.

Nasdaq notified Artelo on Jan 14, 2026 of non-compliance with the Annual Meeting Rule (5620(a)).
Annual meeting adjourned from Dec 31, 2025 to Jan 30, 2026 due to insufficient quorum.
Non-compliance is an additional basis for delisting; company already under equity deficiency (Rule 5550(b)(1)).
Company will take measures to regain compliance; stock continues trading pending hearing panel decision.
No assurance that appeal of equity deficiency delisting determination will succeed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

January 14, 2026, the Company received a letter from the Staff of Nasdaq (the “Nasdaq Notice”) indicating that it is not in compliance with Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires companies listed on Nasdaq to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year-end, and, as a result, does not currently satisfy the Annual Meeting Rule. The Staff indicated in the Nasdaq Notice that the Company’s non-compliance with the Annual Meeting Rule could be an additional basis for a delisting determination. The Company ac

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.